Neurocrine Biosciences (NBIX) Tops Q1 EPS by 77c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $142.70 -0.41%
Revenue Growth %: +30.8%
Financial Fact:
Total revenues: 0
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +30.8%
Financial Fact:
Total revenues: 0
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of $1.94, $0.77 better than the analyst estimate of $1.17. Revenue for the quarter came in at $811 million versus the consensus estimate of $766.85 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kotak Upgrades Indusind Bank Ltd (IIB:IN) to Reduce (3)
- Axis Capital Limited Reiterates Buy (1) Rating on Tata Motors (TMCV:IN)
- Tata Motors (TMCV:IN) PT Raised to INR645 at UBS
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
